Immunome Inc. (IMNM) FY2025 10-K Annual Report
Immunome Inc. (IMNM) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 3, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Immunome Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: Development and commercialization of first- and best-in-class targeted oncology therapies with focus on antibody-drug conjugates (ADCs) and radioligand therapies (RLTs)
- • New emphasis on varegacestat for desmoid tumors with positive Phase 3 results and planned NDA submission Q2 2026
Management Discussion & Analysis
- • Collaboration revenue $6.9M, down $2.1M YoY from $9.0M, ceasing after July 2025 termination
- • Operating margin improvement: operating loss $224.1M vs $305.8M, R&D expenses up to $177.3M vs $129.5M, G&A $43.8M vs $33.0M
Risk Factors
- • Cybersecurity risk with potential regulatory fines, litigation, operational disruption, and reputational harm from IT system compromises
- • Key-person dependency on three senior IT officers managing cybersecurity, including Head of IT and Senior Director with 30+ years biotech experience
Immunome Inc. FY2025 Key Financial MetricsXBRL
Revenue
$7M
▼ -23.2% YoY
Net Income
-$212M
▲ +27.5% YoY
Operating Margin
-3228.8%
▲ +15354bp YoY
Net Margin
-3060.0%
▲ +18039bp YoY
ROE
-33.5%
▲ +12823bp YoY
Total Assets
$683M
▲ +184.4% YoY
EPS (Diluted)
$-2.43
▲ +51.4% YoY
Operating Cash Flow
-$191M
▼ -72.3% YoY
Source: XBRL data from Immunome Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Immunome Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.